Warning: mkdir(): Permission denied in /home/virtual/lib/view_data.php on line 81

Warning: fopen(upload/ip_log/ip_log_2024-03.txt): failed to open stream: No such file or directory in /home/virtual/lib/view_data.php on line 83

Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84
Clinical evaluation of praziquantel(Embay 8440; Biltricide®) in the treatment of Paragonimus westermani
| Home | E-Submission | Sitemap | Contact us |  
top_img
Korean J Parasito Search

CLOSE

Korean J Parasito > Volume 19(1):1981 > Article

Original Article
Korean J Parasitol. 1981 Aug;19(1):27-37. English.
Published online Mar 20, 1994.  http://dx.doi.org/10.3347/kjp.1981.19.1.27
Copyright © 1981 by The Korean Society for Parasitology
Clinical evaluation of praziquantel(Embay 8440; Biltricide®) in the treatment of Paragonimus westermani
Han-Jong Rim,Yoo-Shin Chang,Joon-Sang Lee,Kyoung-Hwan Joo,Won-Hyuk Suh,* and Moriyasu Tsuji
Department of Parasitology and Institute for Tropical Endemic Diseases, College of Medicine, Korea University, Seoul, Korea.
*Department of Radiology, College of Medicine, Korea University, Seoul, Korea.
Department of Parasitology, School of Medicine, Hiroshima University, Hiroshima, Japan.
Abstract

A total of 52 paragonimiasis patients was treated with praziquantel at three dose levels: 21 patients received 3 × 25.0 mg/kg bwt on a single day, 21 patients were treated with 3 × 25.0 mg/kg for 2 consecutive days and 10 patients were treated with the same dose for 3 consecutive days. Follow-up examination were carried out at monthly up to 4 months (120 days) after treatment. Fifteen (71.4%) out of 21 patients who received the drug 3 × 25.0 mg/kg bwt on a single day were parasitologically cured. Eighteen (85.7%) out of 21 patients who received 3 × 25.0 mg/kg bwt for 2 consecutive days were also cured. Six and 3 of uncured cases in each above groups were treated again with doses of 3 × 25.0 mg/kg bwt for 2 or 3 consecutive days. Two (consisting each one in each group ) of nine retreated cases were failed in parasitological cure. Therefore the overall cure rates of 95.2 % (20 out of 21 cases) in each group were finally obtained. On the other hand, in 10 patients who received 3 × 25.0 mg/kg bwt for 3 consecutive days, complete cure was obtained at 4 months follow-up examinations.

Praziquantel is well tolerated and side effects consist particularly of mild and transient headache and dizziness. There was no great difference between the three dosage groups. Extended hematological and biochemical tests, and urinalysis, revealed no abnormal findings which could be related to the compound after therapy.

The disappearance of precipitating bands of immunoelectrophoresis together with the disappearance of abnormal shawdows in chest X-ray after treatment gave a potent proof on assuring the cure of paragonimiasis.

Tables


Table 1
The use of praziquantel in human paragonimiasis. Characteristics of the study group in relation to the degree of infection and allocation to dosages


Table 2
The use of praziquantel in human paragonimiasis. Ratio of patients cured in follow-up after 1st and 2nd treatment with three dosages


Table 3
Therapeutic effects of praziquantel in the treatment of paragonimiasis by the degree of infection


Table 4
Frequency of symptoms in paragonimiasis patients before and after treatment with praziquantel


Table 5
The changes of the chest X-ray abnormalities before and after treatment with praziquantel in paragonimiasis


Table 6
Results of therapeutic efficacy and immunoelectrophoresis in paragonimiasis patients treated with praziquantel

References
1. Davis A, Biles JE, Ulrich AM. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ 1979;57(5):773–779.
 
2. Katz N, Rocha RS, Chaves A. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull World Health Organ 1979;57(5):781–785.
 
3. Nwokolo C, Volkmer KJ. Single dose therapy of paragonimiasis with menichlopholan. Am J Trop Med Hyg 1977;26(4):688–692.
 
4. Rim HJ. Korea Univ Med J 1975;12:425–457.
5. Rim HJ, et al. Korea Univ Med J 1980;17:113–128.
6. Rim HJ, Chu DS, Lee JS, Joo KH, Won CY. [Anthelmintic Effects Of Various Drugs Against Metagonimiasis]. Korean J Parasitol 1978;16(2):117–122.
 
7. Rim HJ, Chu DS, Lee JS, Joo KH, Won CY. [Anthelmintic Effects Of Various Drugs Against Metagonimiasis]. Korean J Parasitol 1978;16(2):117–122.
 
8. Rim HJ, et al. Korea Univ Med J 1979;16:167–182.
9. Rim HJ, Lyu KS, Lee JS, Joo KH. Clinical evaluation of the therapeutic efficacy of praziquantel (Embay 8440) against Clonorchis sinensis infection in man. Ann Trop Med Parasitol 1981;75(1):27–33.
 
10. Rim HJ, et al. Korea Univ Med J 1979;16:459–470.
11. Santos AT, Blas BL, Noseñas JS, Portillo GP, Ortega OM, Hayashi M, Boehme K. Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull World Health Organ 1979;57(5):793–799.
 
12. Yokogawa M, et al. Jpn J Parasit 1961;10:302–316.
13. Yokogawa M, et al. Jpn J Parasit 1961;10:317–327.
14. Yokogawa M, Iwasaki M, Shigeyasu M, Hirose H, Okura T, Tsuji M. Chemotherapy of paragonimiasis with bithionol. V. Studies on the minimum effective dose and changes in abnormal X-Ray shadows in the chest after treatment. Am J Trop Med Hyg 1963;12:859–869.
 
Editorial Office
Department of Molecular Parasitology, Samsung Medical Center, School of Medicine, Sungkyunkwan University,
2066 Seobu-ro, Jangan-gu, Suwon 16419, Gyeonggi-do, Korea.
Tel: +82-31-299-6251   FAX: +82-1-299-6269   E-mail: kjp.editor@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © 2024 by The Korean Society for Parasitology and Tropical Medicine.     Developed in M2PI